Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01247363 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2608204 in Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01247363 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 20 participants.
The verdict
NCT01247363, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Safety study with multiple oral doses of LY2608204 given to patients with type 2 diabetes. Study subjects will receive once daily doses of LY2608204 for a total treatment duration of up to 28 days. In this study, each patient will receive increasing doses of LY2608204 until reaching the highest dose that they can tolerate. Continuous glucose monitoring devices will be employed for each patient to monitor for hypoglycemia during study treatment. Dose titration and dose reduction is determined for each individual patient based on their safety and glycemic data.
Interventions
- DRUG LY2608204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01247363
The ClinicalTrials.gov registry entry for NCT01247363 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2608204 is the first listed.
NCT01247363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01247363 about?
NCT01247363 is a clinical study titled "A Study of LY2608204 in Patients With Type 2 Diabetes". Safety study with multiple oral doses of LY2608204 given to patients with type 2 diabetes. Study subjects will receive once daily doses of LY2608204 for a total treatment duration of up to 28 days. In this study, each patient will receive increasing doses of LY2608204 until reaching the highest dose...
What is the current status of trial NCT01247363?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01247363?
The interventions under investigation include: LY2608204 (DRUG).
Who is sponsoring clinical trial NCT01247363?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.